1. Home
  2. BIVI vs RFL Comparison

BIVI vs RFL Comparison

Compare BIVI & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIVI
  • RFL
  • Stock Information
  • Founded
  • BIVI 2013
  • RFL 2017
  • Country
  • BIVI United States
  • RFL United States
  • Employees
  • BIVI N/A
  • RFL N/A
  • Industry
  • BIVI Biotechnology: Pharmaceutical Preparations
  • RFL Real Estate
  • Sector
  • BIVI Health Care
  • RFL Finance
  • Exchange
  • BIVI Nasdaq
  • RFL Nasdaq
  • Market Cap
  • BIVI 49.8M
  • RFL 55.3M
  • IPO Year
  • BIVI N/A
  • RFL N/A
  • Fundamental
  • Price
  • BIVI $1.90
  • RFL $1.92
  • Analyst Decision
  • BIVI Strong Buy
  • RFL
  • Analyst Count
  • BIVI 1
  • RFL 0
  • Target Price
  • BIVI $30.00
  • RFL N/A
  • AVG Volume (30 Days)
  • BIVI 1.5M
  • RFL 30.6K
  • Earning Date
  • BIVI 02-11-2025
  • RFL 01-03-2025
  • Dividend Yield
  • BIVI N/A
  • RFL N/A
  • EPS Growth
  • BIVI N/A
  • RFL N/A
  • EPS
  • BIVI N/A
  • RFL N/A
  • Revenue
  • BIVI N/A
  • RFL $697,000.00
  • Revenue This Year
  • BIVI N/A
  • RFL N/A
  • Revenue Next Year
  • BIVI N/A
  • RFL N/A
  • P/E Ratio
  • BIVI N/A
  • RFL N/A
  • Revenue Growth
  • BIVI N/A
  • RFL 151.62
  • 52 Week Low
  • BIVI $1.04
  • RFL $1.29
  • 52 Week High
  • BIVI $33.10
  • RFL $2.50
  • Technical
  • Relative Strength Index (RSI)
  • BIVI 30.38
  • RFL 53.58
  • Support Level
  • BIVI $2.41
  • RFL $1.71
  • Resistance Level
  • BIVI $2.70
  • RFL $1.92
  • Average True Range (ATR)
  • BIVI 0.23
  • RFL 0.10
  • MACD
  • BIVI -0.12
  • RFL -0.00
  • Stochastic Oscillator
  • BIVI 0.00
  • RFL 84.00

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: